Objectives:  Prostate cancer (PC) is the second most common cancer in men worldwide and the second leading cause of cancer deaths in men in the United States.  Recently, the prostate specific antigen (PSA) test used to screen and diagnosis PC has been questioned due to concerns regarding clinical utility and its inability to accurately identify men with PC.  This research aims to estimate the Value of Information (VoI) of the PSA screening research and to determine whether future PSA screening research should be focused on specific populations. Methods:  This research uses the Minimal Modeling Approach (MMA) in order to determine the expected value of information for PSA research.  The population expected value of information (pEVI) for racial (African Americans and non-African Americans) and age (65-75 years, 76-85 years, >85 years) subgroups will be determined. Investigators will model survival based on published randomized controlled trials of PSA screening and will use data from the Surveillance Epidemiology and End-Result (SEER)-Medicare dataset for both survival and costs. Investigators will structure analyses by modeling the net benefit of men who received a prostate specific antigen screening exam between 2000 and 2007. Resuts: VoI is recognized for providing a framework for estimating the expected benefits of clinical research.  Due to the controversy surrounding the PSA screening test, patients and clinicians are challenged when trying to make informed decisions regarding diagnosis and treatment of PC. Conclusions: This research seeks to determine where the greatest return on research investment would provide a more accurate evidence base for PSA screening for PC.